RecruitingPhase 4NCT06818474
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Studying Acquired angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bernstein Clinical Research Center
- Principal Investigator
- Jonathan Bernstein, MD5139314181
- Intervention
- Lanadelumab 300 mg(biological)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06818474 on ClinicalTrials.gov